Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Buy
51
COGT Quote, Financials, Valuation and Earnings
Last price:
$37.82
Seasonality move
:
-19.09%
Day range:
$35.09 - $38.36
52-week range:
$3.72 - $43.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.99x
P/B ratio:
29.82x
Volume:
1.9M
Avg. volume:
2.5M
1-year change:
412.75%
Market cap:
$5.8B
Revenue:
--
EPS (TTM):
-$2.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.51 | -- | -5.68% | $50.25 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 26.61% | 81.82% | $25.67 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.56 | -100% | -70.51% | $221.50 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$152.8M | -$1.25 | 49.66% | -49.23% | $90.49 |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.53 | -- | -50.05% | $45.30 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.95% | 42.9% | $28.66 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
$37.79 | $50.25 | $5.8B | -- | $0.00 | 0% | 55.99x |
|
ADMA
ADMA Biologics, Inc.
|
$18.28 | $25.67 | $4.4B | 21.47x | $0.00 | 0% | 9.20x |
|
CDTX
Cidara Therapeutics, Inc.
|
$221.38 | $221.50 | $7B | -- | $0.00 | 0% | 55.23x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$78.87 | $90.49 | $12.8B | -- | $0.00 | 0% | 13.43x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$28.77 | $45.30 | $2B | -- | $0.00 | 0% | -- |
|
PFE
Pfizer Inc.
|
$25.58 | $28.66 | $145.4B | 14.91x | $0.43 | 6.72% | 2.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
16.68% | 3.048 | 2.86% | 6.28x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 4.188 | 0.07% | 4.47x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.510 | 19.43% | 2.51x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | -0.039 | 0.67% | 7.90x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-$1.1M | -$83.4M | -103.58% | -117.99% | -- | -$64.4M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Cogent Biosciences, Inc. vs. Competitors
-
Which has Higher Returns COGT or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 27.14%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About COGT or ADMA?
Cogent Biosciences, Inc. has a consensus price target of $50.25, signalling upside risk potential of 32.97%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 40.41%. Given that ADMA Biologics, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 ADMAADMA Biologics, Inc.3 0 0 -
Is COGT or ADMA More Risky?
Cogent Biosciences, Inc. has a beta of 0.504, which suggesting that the stock is 49.585% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock COGT or ADMA?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or ADMA?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 21.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 9.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M ADMAADMA Biologics, Inc.9.20x 21.47x $134.2M $36.4M
-
Which has Higher Returns COGT or CDTX?
Cidara Therapeutics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -30201.66%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About COGT or CDTX?
Cogent Biosciences, Inc. has a consensus price target of $50.25, signalling upside risk potential of 32.97%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Cogent Biosciences, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 CDTXCidara Therapeutics, Inc.0 3 0 -
Is COGT or CDTX More Risky?
Cogent Biosciences, Inc. has a beta of 0.504, which suggesting that the stock is 49.585% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.523, suggesting its more volatile than the S&P 500 by 52.269%.
-
Which is a Better Dividend Stock COGT or CDTX?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or CDTX?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns COGT or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -82.06%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About COGT or IONS?
Cogent Biosciences, Inc. has a consensus price target of $50.25, signalling upside risk potential of 32.97%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.49 which suggests that it could grow by 14.73%. Given that Cogent Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is COGT or IONS More Risky?
Cogent Biosciences, Inc. has a beta of 0.504, which suggesting that the stock is 49.585% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.
-
Which is a Better Dividend Stock COGT or IONS?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or IONS?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 13.43x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M IONSIonis Pharmaceuticals, Inc.13.43x -- $156.7M -$128.6M
-
Which has Higher Returns COGT or OLMA?
Olema Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M -
What do Analysts Say About COGT or OLMA?
Cogent Biosciences, Inc. has a consensus price target of $50.25, signalling upside risk potential of 32.97%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $45.30 which suggests that it could grow by 57.46%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 OLMAOlema Pharmaceuticals, Inc.9 0 0 -
Is COGT or OLMA More Risky?
Cogent Biosciences, Inc. has a beta of 0.504, which suggesting that the stock is 49.585% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.919, suggesting its more volatile than the S&P 500 by 91.942%.
-
Which is a Better Dividend Stock COGT or OLMA?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or OLMA?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M
-
Which has Higher Returns COGT or PFE?
Pfizer Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 21.32%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About COGT or PFE?
Cogent Biosciences, Inc. has a consensus price target of $50.25, signalling upside risk potential of 32.97%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.03%. Given that Cogent Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 PFEPfizer Inc.7 15 1 -
Is COGT or PFE More Risky?
Cogent Biosciences, Inc. has a beta of 0.504, which suggesting that the stock is 49.585% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock COGT or PFE?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.72% to investors and pays a quarterly dividend of $0.43 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or PFE?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M PFEPfizer Inc.2.33x 14.91x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 17.03% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is down 12.42% over the past day.
Sell
43
VKTX alert for Jan 15
Viking Therapeutics, Inc. [VKTX] is up 11.83% over the past day.
